#4305
Lower dose of lenvatinib is similarly effective as higher dose for patients (pts) with advanced neuroendocrine tumours (NETs): A multinational retrospective cohort
Introduction:
A phase II trial with lenvatinib 24mg PO daily was effective for pts with gastroenteropancreatic (GEP) NETs but led to significant toxicity. In clinical practice, dose reductions are commonly required.
Conference:
Presenting Author:
Riechelmann R
Authors:
Zanetta G,
Grozinsky-Glasberg S,
Bel-Ange A,
Barros M,
Felismino T,
Keywords:
lenvatinib,
neuroendocrine tumour,
dose optimisation,
toxicity,
#3318
Neuroendocrine tumors in young adult patients - Epidemiological profile, clinical aspects and prognostic factors
Introduction:
Neuroendocrine tumors (NETs) comprise a rare disease. However, an increase in the number of cases in young-onset (18-40 years old) NETs (YONET) has been observed in our clinical practice. The data about YONETs profile are scarce.
Conference:
18th Annual ENETS Concerence (2021)
Presenting Author:
Zanco Fogassa C
Authors:
Fogassa C,
Camandaroba M,
Tanaka H,
Felismino T,
Riechelmann R,
Keywords:
young-onset NETs,
NET,
gastroenteropancreatic NETs,
#2828
G3 Neuroendocrine Tumours and Carcinomas: Clinicopathological Features for Distinct Entities
Introduction:
The 2019 WHO subclassified the grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) into neuroendocrine carcinoma (NEC) or tumors (G3 NET). Yet, few data exist on clinical and treatment profiles for G3 NET.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Taboada R
Authors:
Taboada R,
Claro L,
Campos F,
Felismino T,
de Jesus V,
Keywords:
neuroendocrine,
high grade,
clinicopathological,
carcinoma,
G3,
#2712
HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression
Introduction:
We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Riechelmann R
Authors:
Riechelmann R,
Donadio M,
Felismino T,
Fonseca de Jesus V,
Mello C,
Keywords:
neuroendocrine,
estrogen,
progesterone,
clinical trial,
